NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 109 filers reported holding NURIX THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $70,826 | -28.5% | 9,011 | -9.1% | 0.04% | -27.1% |
| Q2 2023 | $99,021 | +36.3% | 9,912 | +21.2% | 0.06% | +47.5% |
| Q1 2023 | $72,647 | -41.6% | 8,181 | -27.8% | 0.04% | -38.5% |
| Q4 2022 | $124,425 | -11.8% | 11,332 | +4.8% | 0.06% | +16.1% |
| Q3 2022 | $141,000 | +3.7% | 10,813 | +0.7% | 0.06% | +12.0% |
| Q2 2022 | $136,000 | +70.0% | 10,735 | +89.1% | 0.05% | +38.9% |
| Q1 2022 | $80,000 | -54.0% | 5,676 | -5.6% | 0.04% | -45.5% |
| Q4 2021 | $174,000 | -19.4% | 6,010 | -16.4% | 0.07% | -30.5% |
| Q3 2021 | $216,000 | +7.5% | 7,193 | -5.0% | 0.10% | +14.5% |
| Q2 2021 | $201,000 | – | 7,570 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ponoi II Management, LLC | 561,574 | $16,825,000 | 24.93% |
| Ponoi Management, LLC | 561,573 | $16,825,000 | 14.94% |
| TRV GP III, LLC | 2,422,549 | $72,580,000 | 13.78% |
| Foresite Capital Management IV, LLC | 1,205,798 | $36,126,000 | 5.32% |
| Foresite Capital Management V, LLC | 451,522 | $13,528,000 | 4.20% |
| WestHill Financial Advisors, Inc. | 283,333 | $8,489,000 | 2.62% |
| DAFNA Capital Management LLC | 306,320 | $9,177,000 | 2.44% |
| Bain Capital Life Sciences Investors, LLC | 1,284,314 | $38,478,000 | 2.39% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 571,212 | $17,113,000 | 2.02% |
| Redmile Group, LLC | 3,093,077 | $92,669,000 | 1.62% |